Helicobacter pylori 양성 만성 위염 및 위궤양 환자에 대한 제균요법 후 Rebamipide 유지요법의 유용성

Background/Aims: The aim of this study was to investigate the usefulness of rebamipide maintenance therapy after eradication of H. pylori. Thus, we compared the changes of various inflammatory or local immunologic parameters before and after the therapy. Methods: Fifty-two patients with H. pylori-positive gastritis or gastric ulcer received the treatment consisted of omeprazole, amoxacillin and metronidazole for 2 weeks, and randomly divided into two groups. Group Ⅰ received a six-week supply of ranitidine plus rebamipide (100 mg t.i.d.). Group Ⅱ received a six-week supply of ranitidine plus teprenone (50 mg t.i.d.). For the two groups, we compared clinical symptoms, status of H. pylori infection, the degree of inflammatory cell infiltration, and the local secretion of cytokines. Results: After rebamipide therapy, symptom scores, and the degree of inflammatory cell infiltration in gastric mucosa were markedly reduced in the both groups (p 0.05). Conclusions: Rebamipide therapy after H. pylori eradication is efficacious against various gastrointestinal symptoms, inflammatory responses, and maintains host immunity. (Kor J Gastroenterol 2000;36:175 - 184)